



UNIVERSITI PUTRA MALAYSIA

**THE HYPOGLYCAEMIC ACTIVITY OF MENGKUDU
(*MORINDA CITRIFOLIA*)**

CHEE BENG JIN

FSAS 2001 49

**THE HYPOGLYCAEMIC ACTIVITY OF MENGKUDU
(*MORINDA CITRIFOLIA*)**

By

CHEE BENG JIN

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfilment of the Requirements for the Degree of Master of Science**

November 2001



A Work,
Dedicated to...

My parents, brother and my beloved family members,
Relatives and friends,
Brothers and sisters in Christ,
Diabetes research.

Worship the LORD your God,
and his blessings will
be on your food and water.
I will take away sickness from
among you.

Exodus 23:25

Chee Beng Jin
Biology Department,
Universiti Putra Malaysia,
43400 Serdang.

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment
of the requirement for the degree of Master of Science

**THE HYPOGLYCAEMIC ACTIVITY OF MENGKUDU
(*MORINDA CITRIFOLIA*)**

By

CHEE BENG JIN

November 2001

Chairman: Associate Professor Hamdan Noor, Ph.D.

Faculty: Science and Environmental Studies

Diabetes mellitus has existed for at least 2000 years and has been treated with materials derived from plants in many cultures of the world. The mengkudu (*Morinda citrifolia*) are known for countless medicinal values and the ripe fruits were being used traditionally in Malaysia for the treatment for diabetes mellitus. This study was carried out to verify the hypoglycaemic property and its possible effect on insulin secretion. Freeze-dried aqueous extracts of various doses of 3mg/kg, 30mg/kg and 300mg/kg were administered to normal rats in an acute effect study and the doses of 3mg/kg, 30mg/kg, 300mg/kg, 600mg/kg, 900mg/kg and 1200mg/kg were administered to streptozotocin induced type 2 diabetic rats in a chronic effect study in an Oral Glucose Tolerance Test (OGTT). Results from the chronic effect study showed that the 300mg/kg dose treated rats had an apparent hypoglycaemic effect as evident from the blood glucose level measured as the area under the OGTT curve (AUC: 4370.70 ± 99.13 mg%min) after 6 weeks of oral administration. Hypoglycaemic activity was also observed in the 600mg/kg dose after 5 weeks of oral administration (AUC: 4486.70 ± 35.60 mg%min), the 900mg/kg dose after 4 weeks of oral administration (AUC: 4340.40 ± 72.90 mg%min) and the 1200mg/kg dose after 4 weeks of oral administration (AUC: 4554.00 ± 49.80 mg%min). All the

AUC values were significantly lower compared to control. The aqueous extracts were also able to impede the rate of glucose increase and enhance the glucose clearance. However, the results from the insulin assay did not show any significant change in the insulin release profile as compared to control. As a conclusion, the aqueous extract of mengkudu (*Morinda citrifolia*) fruit preparations in the doses of 300mg/kg, 600mg/kg, 900mg/kg and 1200mg/kg might contain plant compounds that have substantial hypoglycemic property only in the chronic effect study but did not affect the insulin secretion in the type 2 diabetic rats. Future studies should be carried out in order to further discover its mechanisms of action, isolation and identification of the hypoglycaemic components particularly with regard to the healing of diabetes by means of plant resources.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia
sebagai memenuhi keperluan untuk ijazah Master Sains

AKTIVITI HIPOGLISEMIK BUAH MENGKUDU (*MORINDA CITRIFOLIA*)

Oleh

CHEE BENG JIN

November 2001

Pengerusi: Profesor Madya Hamdan Noor, Ph.D.

Fakulti: Sains dan Pengajian Alam Sekitar

Penyakit diabetes mellitus telah dikesan semenjak 2000 tahun dahulu dan cara rawatannya dengan menggunakan tumbuhan telah dikenalpasti di pelbagai kebudayaan di merata dunia. Mengkudu (*Morinda citrifolia*) amat terkenal dengan pelbagai nilai perubatan dan telah digunakan secara tradisional untuk merawat diabetes mellitus di Malaysia. Objektif eksperimen ini ialah untuk membuktikan kesan hipoglisemik dan kesannya terhadap perembesan hormon insulin. Ekstrak buah berakua yang telah disejukbekukan telah diberikan kepada tikus normal (3mg/kg, 30mg/kg dan 300mg/kg) untuk kajian kesan akut dan tikus diabetik jenis 2 (3mg/kg, 30mg/kg, 300mg/kg, 600mg/kg, 900mg/kg dan 1200mg/kg) untuk kajian kesan kronik di dalam Ujian Toleransi Glukosa. Keputusan kajian kesan kronik menunjukkan bahawa tikus kajian yang diberikan dos 300mg/kg mempunyai aras glukosa darah yang lebih rendah berdasarkan nilai keluasan dibawah graf (AUC: $4370.70 \pm 99.13 \text{ mg}\% \text{min}$) setelah rawatan oral selama 5 minggu. Kesan hipoglisemik juga diperhatikan untuk dos 600mg/kg selepas rawatan 5 minggu (AUC: $4486.70 \pm 35.60 \text{ mg}\% \text{min}$), dos 900mg/kg selepas rawatan 4 minggu (AUC: $4340.40 \pm 72.90 \text{ mg}\% \text{min}$) dan dos 1200mg/kg juga selepas 4 minggu rawatan (AUC: $4554.00 \pm 49.80 \text{ mg}\% \text{min}$). Kesemua nilai keluasan di bawah graf (AUC)

adalah lebih rendah berbanding dengan kumpulan kawalan.. Ekstrak berakua tersebut juga berupaya untuk merendahkan kadar peningkatan glukosa darah dan mempercepatkan kadar penghapusan glukosa darah. Walau bagaimanapun, keputusan ujian aras insulin menunjukkan bahawa ekstrak tersebut tidak mempengaruhi corak perembesan hormon insulin. Sebagai kesimpulan ekstrak berakua buah mengkudu (*Morinda citrifolia*) berdos 300mg/kg, 600mg/kg, 900mg/kg dan 1200mg/kg berupaya untuk merendahkan aras glukosa darah tikus diabetik jenis 2 di dalam kajian kronik sahaja dan tidak mempengaruhi perembesan hormon insulin. Berdasarkan kepada keputusan ini, kajian lanjutan masih perlu dilakukan untuk mengkaji mekanisme tindakannya, pengasingan dan pengenalpastian komponen-komponen hipoglisemik di dalam ekstrak tersebut seiringan dengan kajian untuk rawatan diabetes mellitus dengan menggunakan sumber tumbuhan tempatan.

ACKNOWLEDGEMENTS

My sincere praises and thanksgiving to God Almighty for His unfailing love and grace in guiding me to complete my Master of Science project successfully.

I am very grateful to my supervisors, Associate Professor Dr. Hamdan Noor, Associate Professor Dr. Umi Kalsom Yusuf and Encik Zolkepli Othman. Remembering you for your patience and assistance throughout my work.

My warmest gratitude to Encik Haji Nordin Kassim for guiding and passing on your experiences and advices on animal physiology experiments.

Last but not least, thanking my beloved family members, friends, Animal Physiology Team, all the academic and non-academic staff in the Biology Department.

The prayers, time, effort, energy and finances sacrificed throughout the years are indeed a memorable event in my life. May God bless each one of you abundantly.

Amen.

I certify that an Examination Committee met on 5th November 2001 to conduct the final examination of Mr. Chee Beng Jin on his Master of Science thesis entitled "The Hypoglycaemic Activity of Mengkudu (*Morinda citrifolia*)" in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The Committee recommends that the candidates be awarded the relevant degree. Members of the Examination Committee are as follows:

ABDUL SALAM ABDULLAH, Ph.D.
Professor,
Faculty of Veterinary Medicine,
Universiti Putra Malaysia.
(Chairman)

HAMDAN NOOR, Ph.D.
Associate Professor,
Faculty of Science and Environmental Studies,
Universiti Putra Malaysia.
(Member)

UMI KALSOM YUSUF, Ph.D.
Associate Professor,
Faculty of Science and Environmental Studies,
Universiti Putra Malaysia.
(Member)

ZOLKEPLI OTHMAN,
Faculty of Science and Environmental Studies,
Universiti Putra Malaysia.
(Member)



SHAMSHER MOHAMAD RAMADILI, Ph.D.
Professor/Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 13 MAY 2002

The thesis submitted to the Senate of Universiti Putra Malaysia has been accepted as fulfilment of the requirement for the degree of Master Science.



AINI IDERIS, Ph.D.
Professor/Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: **13** June 2012

DECLARATION

I hereby declare that the thesis is based on my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously or concurrently submitted for any other degree at UPM or other institutions



Chee Beng Jin

Date: 13th May 2002

TABLE OF CONTENTS

	Page
DEDICATION	
ABSTRACT	3
ABSTRAK	5
ACKNOWLEDGEMENTS	7
APPROVAL SHEETS	8
DECLARATION FORMS	10
TABLE OF CONTENTS	11
LIST OF TABLES	13
LIST OF FIGURES	16
LIST OF ABBREVIATIONS	20
 CHAPTER	
 1 INTRODUCTION	 21
 2 LITERATURE REVIEW	
2.1 The Regulation of Blood Glucose Level	25
2.2 Diabetes Mellitus	
2.2.1 Type 1 Diabetes Mellitus	28
2.2.2 Type 2 Diabetes Mellitus	30
2.2.3 Glibenclamide	31
2.3 Modern Treatment for Diabetes Mellitus and Side Effects	32
2.4 Plants with Hypoglycaemic Property	37
2.5 Hypoglycaemic Mechanism of Plant Extract	
2.5.1 Stimulation of Insulin Secretion	44
2.5.2 Reduction of Hepatic Glucose Output	47
2.5.3 Fiber in Blood Glucose Regulation	49
2.5.4 Insulin-like Compounds or Chemicals	56
2.5.5 Other Proposed Mechanisms	58
2.6 <i>Morinda citrifolia</i> : A Plant of Many Uses	59
2.6.1 Traditional Use of <i>M. citrifolia</i>	60
2.6.2 Scientific Research on <i>M. citrifolia</i>	63
2.6.3 The <i>Morinda citrifolia</i> Plant as a Traditional Cure for Diabetes	67
 3 METHODOLOGY.	
3.1 Type 2 Diabetic Rat Model	68
3.2 Plant Extract Preparation	68
3.3 Experimental Design.	68
3.4 Oral Glucose Tolerance Test (OGTT).	69
3.5 Blood Glucose Assay	69
3.6 Blood Insulin Assay	70
3.6.1 Insulin Hormone Level Test	70
3.7 Statistical Analysis	71

4	RESULTS	
4.1	Hypoglycaemic Studies	
4.1.1	Acute Effect Study (3mg/kg, 30mg/kg, 300mg/kg)	72
4.1.2	Chronic Effect Study	
4.1.2.1	Aqueous Fruit Extract (3mg/kg, 30mg/kg, 300mg/kg)	78
4.1.2.2	Aqueous Fruit Extract (600mg/kg, 900mg/kg, 1200mg/kg)	94
4.1.3	Area Under Curves (AUCs) for Glucose Level (mg%amin)	
4.1.3.1	Aqueous Fruit Extract (3mg/kg, 30mg/kg, 300mg/kg)	107
4.1.3.2	Aqueous Fruit Extract (600mg/kg, 900mg/kg, 1200mg/kg)	113
4.2	Insulin Studies	
4.2.1	Blood Insulin Level in Chronic Effect Study	
4.2.1.1	Aqueous Fruit Extract (3mg/kg, 30mg/kg, 300mg/kg)	120
4.2.1.2	Aqueous Fruit Extract (600mg/kg, 900mg/kg, 1200mg/kg)	127
4.2.2	Area Under Curves (AUCs) for Insulin Level (pg/mlmin)	
4.2.2.1	Aqueous Fruit Extract (3mg/kg, 30mg/kg, 300mg/kg)	135
4.2.2.2	Aqueous Fruit Extract (600mg/kg, 900mg/kg, 1200mg/kg)	138
4.3	Rate of Glucose Increase and Decrease	
4.3.1	Aqueous Fruit Extract (3mg/kg, 30mg/kg, 300mg/kg)	141
4.3.2	Aqueous Fruit Extract (600mg/kg, 900mg/kg, 1200mg/kg)	143
5	DISCUSSION	
5.1	Experimental Animal and Blood Sampling	145
5.2	Type 2 Diabetic Model	146
5.3	Hypoglycaemic Property of the Aqueous Extracts	147
5.4	Effect of the Aqueous Extract on Insulin	153
5.5	Possible Hypoglycaemic Effect of <i>Morinda citrifolia</i> Aqueous Extract	155
6	CONCLUSION	157
	REFERENCES	160
	APPENDICES	174
	BIODATA OF THE AUTHOR	220

LIST OF TABLES

Table		Page
1	The blood glucose level for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at different time intervals in the acute effect study	74
2	Area under glucose tolerance curves for different treatments (3mg/kg, 30mg/kg and 300mg/kg) in the acute effect study	75
3	Rate of glucose increase for saline, glibenclamide, 3mg/kg, 30mg/kg and 300mg/kg dose.	76
4	Rate of glucose decrease for saline, glibenclamide, 3mg/kg, 30mg/kg and 300mg/kg dose.	77
5	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Trial 1	80
6	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Trial 2	81
7	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Trial 3	82
8	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 1	83
9	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 2	84
10	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 3	85
11	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 4	86
12	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 5	87
13	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 6	89
14	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 7	90
15	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 8	91

16	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 9	92
17	Blood glucose levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 10	93
18	Blood glucose levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Trial 1	95
19	Blood glucose levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Trial 2	96
20	Blood glucose levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Trial 3	97
21	Blood glucose levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 1	98
22	Blood glucose levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 2	99
23	Blood glucose levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 3	100
24	Blood glucose levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 4	102
25	Blood glucose levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 5	103
26	Blood glucose levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 6	104
27	Blood glucose levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 7	105
28	Blood glucose levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 8	106
29	Area under glucose tolerance curves for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at different weeks	109
30	Area under glucose tolerance curves for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at different weeks	115
31	Blood insulin levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 5	122
32	Blood insulin levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 6	123

33	Blood insulin levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 7	124
34	Blood insulin levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 8	125
35	Blood insulin levels for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 9	126
36	Blood insulin levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 3	129
37	Blood insulin levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 4	130
38	Blood insulin levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 5	131
39	Blood insulin levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 6	132
40	Blood insulin levels for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at Week 7	133
41	Area under insulin curves for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at different weeks	135
42	Area under insulin curves for different treatments (600mg/kg, 900mg/kg and 1200 mg/kg) at different weeks	138
43	Rate of glucose increase for saline, glibenclamide and 300mg/kg dose	141
44	Rate of glucose decrease for saline, glibenclamide and 300mg/kg dose	142
45	Rate of glucose increase for saline, glibenclamide, 600mg/kg, 900mg/kg and 1200mg/kg dose	143
46	Rate of glucose decrease for saline, glibenclamide, 600mg/kg, 900mg/kg and 1200mg/kg dose	144

LIST OF FIGURES

Figure		Page
1	Blood glucose tolerance curves for different treatments (3mg/kg, 30mg/kg and 300mg/kg) in acute effect study	74
2	Blood glucose tolerance curves for different treatments at Trial 1 (3mg/kg, 30mg/kg and 300mg/kg)	80
3	Blood glucose tolerance curves for different treatments at Trial 2 (3mg/kg, 30mg/kg and 300mg/kg)	81
4	Blood glucose tolerance curves for different treatments at Trial 3 (3mg/kg, 30mg/kg and 300mg/kg)	82
5	Blood glucose tolerance curves for different treatments at Week 1 (3mg/kg, 30mg/kg and 300mg/kg)	83
6	Blood glucose tolerance curves for different treatments at Week 2 (3mg/kg, 30mg/kg and 300mg/kg)	84
7	Blood glucose tolerance curves for different treatments at Week 3 (3mg/kg, 30mg/kg and 300mg/kg)	85
8	Blood glucose tolerance curves for different treatments at Week 4 (3mg/kg, 30mg/kg and 300mg/kg)	86
9	Blood glucose tolerance curves for different treatments at Week 5 (3mg/kg, 30mg/kg and 300mg/kg)	87
10	Blood glucose tolerance curves for different treatments at Week 6 (3mg/kg, 30mg/kg and 300mg/kg)	89
11	Blood glucose tolerance curves for different treatments at Week 7 (3mg/kg, 30mg/kg and 300mg/kg)	90
12	Blood glucose tolerance curves for different treatments at Week 8 (3mg/kg, 30mg/kg and 300mg/kg)	91
13	Blood glucose tolerance curves for different treatments at Week 9 (3mg/kg, 30mg/kg and 300mg/kg)	92
14	Blood glucose tolerance curves for different treatments at Week 10 (3mg/kg, 30mg/kg and 300mg/kg)	93
15	Blood glucose tolerance curves for different treatments at Trial 1 (600mg/kg, 900mg/kg and 1200mg/kg)	95
16	Blood glucose tolerance curves for different treatments at Trial 2 (600mg/kg, 900mg/kg and 1200mg/kg)	96

17	Blood glucose tolerance curves for different treatments at Trial 3 (600mg/kg, 900mg/kg and 1200mg/kg)	97
18	Blood glucose tolerance curves for different treatments at Week 1 (600mg/kg, 900mg/kg and 1200mg/kg)	98
19	Blood glucose tolerance curves for different treatments at Week 2 (600mg/kg, 900mg/kg and 1200mg/kg)	99
20	Blood glucose tolerance curves for different treatments at Week 3 (600mg/kg, 900mg/kg and 1200mg/kg)	100
21	Blood glucose tolerance curves for different treatments at Week 4 (600mg/kg, 900mg/kg and 1200mg/kg)	102
22	Blood glucose tolerance curves for different treatments at Week 5 (600mg/kg, 900mg/kg and 1200mg/kg)	103
23	Blood glucose tolerance curves for different treatments at Week 6 (600mg/kg, 900mg/kg and 1200mg/kg)	104
24	Blood glucose tolerance curves for different treatments at Week 7 (600mg/kg, 900mg/kg and 1200mg/kg)	105
25	Blood glucose tolerance curves for different treatments at Week 8 (600mg/kg, 900mg/kg and 1200mg/kg)	106
26	Area under glucose tolerance curves for saline at different weeks	110
27	Area under glucose tolerance curves for glibenclamide at different weeks	110
28	Area under glucose tolerance curves for 3mg/kg aqueous extract at different weeks	110
29	Area under glucose tolerance curves for 30mg/kg aqueous extract at different weeks	111
30	Area under glucose tolerance curves for 300mg/kg aqueous extract at different weeks	111
31	Areas under glucose tolerance curves for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 6	112
32	Areas under glucose tolerance curves for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 7	112
33	Areas under glucose tolerance curves for different treatments (3mg/kg, 30mg/kg and 300mg/kg) at Week 8	112

34	Area under glucose tolerance curves for saline at different weeks	116
35	Area under glucose tolerance curves for glibenclamide at different weeks	116
36	Area under glucose tolerance curves for 600mg/kg at different weeks	116
37	Area under glucose tolerance curves for 900mg/kg at different weeks	117
38	Area under glucose tolerance curves for 1200mg/kg at different weeks	117
39	Areas under glucose tolerance curves for different treatments (600mg/kg, 900mg/kg and 1200mg/kg) at Week 4	118
40	Areas under glucose tolerance curves for different treatments (600mg/kg, 900mg/kg and 1200mg/kg) at Week 5	118
41	Areas under glucose tolerance curves for different treatments (600mg/kg, 900mg/kg and 1200mg/kg) at Week 6	119
42	Blood insulin curves for different treatments at week 5 (3mg/kg, 30mg/kg and 300mg/kg)	122
43	Blood insulin curves for different treatments at week 6 (3mg/kg, 30mg/kg and 300mg/kg)	123
44	Blood insulin curves for different treatments at week 7 (3mg/kg, 30mg/kg and 300mg/kg)	124
45	Blood insulin curves for different treatments at week 8 (3mg/kg, 30mg/kg and 300mg/kg)	125
46	Blood insulin curves for different treatments at week 9 (3mg/kg, 30mg/kg and 300mg/kg)	126
47	Blood insulin curves for different treatments at week 3 (600mg/kg, 900mg/kg and 1200mg/kg)	129
48	Blood insulin curves for different treatments at week 4 (600mg/kg, 900mg/kg and 1200mg/kg)	130
49	Blood insulin curves for different treatments at week 5 (600mg/kg, 900mg/kg and 1200mg/kg)	131
50	Blood insulin curves for different treatments at week 6 (600mg/kg, 900mg/kg and 1200mg/kg)	132

51	Blood insulin curves for different treatments at week 7 (600mg/kg, 900mg/kg and 1200mg/kg)	134
52	Areas under insulin curves for saline at different weeks	136
53	Areas under insulin curves for glibenclamide at different weeks	136
54	Areas under insulin curves for 3mg/kg aqueous extract at different weeks	136
55	Areas under insulin curves for 30mg/kg aqueous extract at different weeks	137
56	Areas under insulin curves for 300mg/kg aqueous extract at different weeks	137
57	Areas under insulin curves for saline at different weeks	139
58	Areas under insulin curves for glibenclamide at different weeks	139
59	Areas under insulin curves for 600mg/kg aqueous extract at different weeks	139
60	Areas under insulin curves for 900mg/kg aqueous extract at different weeks	140
61	Areas under insulin curves for 1200mg/kg aqueous extract at different weeks	140

LIST OF ABBREVIATIONS

mg%	milligram per 100 milliter
OD	Optical Density
n	number of replicates or individuals
b.w.	body weight
[G]	Blood glucose concentration
[I]	Blood insulin concentration

CHAPTER 1

INTRODUCTION

Diabetes mellitus is currently a major global issue in public health. The occurrence and prevalence of this disease are alarmingly escalating in developing and newly industrialized countries (King, 1993). The prevalence of diabetes worldwide was estimated to be 4% (135 million people) in 1995 and to increase to 5.4% (estimated 300 million people) by the year 2025 (King *et al.*, 1998.)

The World Health Organization (WHO) has recognized 2 major clinical forms of diabetes mellitus, namely Insulin-Dependant Diabetes Mellitus (IDDM) or Type 1 Diabetes Mellitus and Non-Insulin-Dependent Diabetes Mellitus (NIDDM) or Type 2 Diabetes Mellitus. About 90% of all cases of diabetes in developed and developing countries are NIDDM, primarily found in adult of more than 30 years old (WHO Study Group, 1994).

Asia faces the greatest threat of an epidemic of NIDDM. In 1994, over 43 million people in Southern, Southeast and East Asia were estimated to have NIDDM. WHO has recognized that Asia as having a potential increase with 2.5 to 3 times more common diabetes than the situation today. Hence by the year 2010, Asia is estimated to have 138 million diabetic patients (Amos *et al.*, 1997).



In Malaysia, diabetes is a growing concern among the population especially the government and health practitioners. Throughout the six years Healthy Lifestyle Campaign by the Ministry of Health, which started in 1991, diabetes mellitus became the theme for the year 1995. In 1986, the prevalence of the disease in Peninsular Malaysia as reported in the First National Health and Morbidity Survey was 6.3% and in 1995, the Cardiovascular Unit in the Department of Public Health, Ministry of Health reported that the prevalence to at 7.7%. The prevalence seemed to be on the rise. Recognizing diabetes as a growing public health problem in Malaysia, a scope on diabetes was introduced in the Second National Health and Morbidity Survey (NHMS2). It was carried out to provide a comparative picture of the epidemiology of diabetes mellitus in the population of Malaysia within the last ten years since 1986. In 1997, the survey reported that the national prevalence was found to be 8.3% in the population of age 30 years and above. (Ministry of Health, 1999)

The highest occurrence of identified diabetics by ethnicity was amongst Indians (11.5%) and they were considerably higher than other ethnic groups. The prevalence amid Chinese was 6.3% and Malays was 5.2% whilst other Bumiputera had significantly lower prevalence 2.7%. The prevalence of known diabetics by gender showed that males reported to have higher prevalence (5.9%) compared to females (5.8%)(Ministry of Health, 1999).

Undiagnosed diabetes was defined as whole blood capillary glucose level of equal or more than 11.1 mmol/l among those who did not report themselves as known

diabetics. From the survey, the national prevalence of undiagnosed diabetics was 2.5%. By ethnicity, Indians had the highest prevalence of undiagnosed diabetics, which was 3.4% and by gender, females recorded higher prevalence (2.6%) than males (2.5%)(Ministry of Health, 1999).

In Malaysia, a number of reported death cases from the Ministry of Health (1999) were related to heart disease, stroke or chronic renal failure, some of which might be associated to diabetes. It is projected that the number of diabetics will be rising from 418,000 cases in 1994 to 810,000 cases and 1,201,000 estimated cases in year 2000 and 2010 respectively (Ministry of Health, 1999)

The Ministry of Health in Malaysia has reported that in 1994, about 4.3% of diabetic patients seek treatment in private and government hospitals and about 0.9% seeks treatment in traditional medicine practitioner (Ministry of Health, 1995). Even today, the practice of various traditional medicinal systems are still flourishing in different countries and among different ethnic groups and nearly 80% of the rural population still depend on plant based medicines (Sasson, 1996). About 80% of the rural population in many tropical developing countries still depends on traditional practitioners for their health care, which means that the community has to rely on medicinal plants for treatment (Farnsworth, 1983).

The traditional method of treating diabetes is yet to be explored; Malaysia is richly endowed with diverse flora with good potential to be developed into various useful natural products (Soepadmo, 1993). Our country is known to have a large amount of plant species and a number of them have been traditionally used to treat many disease and ailments. Similar to other diseases, diabetes mellitus has been treated traditionally by oral consumption of plant extracts based on folk and traditional cures since ancient times (Ajgoankar, 1979).